Keyword: Bristol-Myers Squibb
Oncolytic viruses used in tandem with other treatments could be key for difficult-to-treat breast and brain cancers.
The series B gives PGDx the means to pursue approvals of its tissue and liquid biopsy IVD cancer tests in markets around the world.
Pfizer dumped the drug after failing to find signs of efficacy in a phase 1 brain cancer trial, but iTeos thinks it has a future.
French microbiome biotech Enterome has got off a €32 million ($38.5 million) series D round with the help of some big-name players.
FLX Bio has boosted its cash supplies with a new $60 million series C round as it starts dosing for its first cancer test.
Bristol-Myers Squibb has licensed a phase 1 immuno-oncology drug from Japan’s Ono in a $40 million upfront pact.
California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumor microenvironment.
Sanofi and Regeneron have touted new topline data for their midstage checkpoint inhibitor in a certain form of skin cancer this morning.
PsiOxus Therapeutics has a green light for trials of its cancer-killing virus therapy for solid tumors, sparking a $15 million milestone payment.
Doctors in Paris discovered that when they treated an HIV-infected lung cancer patient with Opdivo, reservoirs of the virus shrunk.